Where technical, scientific, and commercial perspectives on AI in biotech unite
Why Now
AI models double as both finished goods and raw materials. In biopharma, this flexibility is reshaping the value network and creating new strategic levers.
June 2, 2026
AI integration falters when its scope is too narrow to prove value or too ambitious for an organization to execute. The strategic window lies where measurable outcomes and organizational preparedness meet.
July 29, 2026
